We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
-25.25%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$257M
AUM Growth
-$9.66M
(-3.6%)
Cap. Flow
+$59.9M
Cap. Flow
% of AUM
23.35%
Top 10 Holdings %
Top 10 Hldgs %
88.62%
Holding
15
New
3
Increased
8
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$21.8M |
| 2 |
Arrowhead Research
ARWR
|
+$17.6M |
| 3 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$17.1M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$12.1M |
| 5 |
uniQure
QURE
|
+$6.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$5.97M |
| 2 |
MRUS
Merus
MRUS
|
+$4.25M |
| 3 |
Fate Therapeutics
FATE
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $77.4M | 30.18% |
1,000,000
-250,000
| -20% | -$22.1M |
|
|
2
uniQure
QURE
$3.22B
| $23.8M | 9.28% |
501,975
+105,076
| +26% | +$6.04M |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $22.7M | 8.86% |
1,237,379
+622,943
| +101% | +$12.1M |
|
|
4
AnaptysBio
ANAB
$1.68B
| $20.3M | 7.93% |
+1,439,079
| New | +$21.8M |
|
5
Xenon Pharmaceuticals
XENE
$6.12B
| $17M | 6.63% |
1,499,970
+333,234
| +29% | +$4.75M |
|
6
Spero Therapeutics
SPRO
$73M
| $14.7M | 5.73% |
1,818,140
+663,784
| +58% | +$5.85M |
|
7
ProQR Therapeutics
PRQR
$265M
| $13.2M | 5.14% |
2,401,570
+479,000
| +25% | +$3.67M |
|
|
NGM
8
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $12.9M | 5.03% |
+1,047,184
| New | +$17.1M |
|
|
PVLA
9
Palvella Therapeutics
PVLA
$2.27B
| $12.7M | 4.95% |
69,694
+7,609
| +12% | +$1.92M |
|
|
10
Arrowhead Research
ARWR
$12.4B
| $12.6M | 4.89% |
+436,514
| New | +$17.6M |
|
|
MRUS
11
DELISTED
Merus
MRUS
| $9.32M | 3.63% |
770,183
-268,563
| -26% | -$4.25M |
|
12
Regenxbio
RGNX
$708M
| $8.85M | 3.45% |
273,211
+4,433
| +2% | +$185K |
|
|
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
| $8.67M | 3.38% |
44,234
-27,733
| -39% | -$5.97M |
|
|
MOR
14
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $2.36M | 0.92% |
95,898
+89,818
| +1,477% | +$2.64M |
|
|
15
Fate Therapeutics
FATE
$326M
| – | – |
-72,273
| Closed | -$1.41M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Aquilo Capital Management held 15 positions worth $257M, down 3.6% from $266M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Aquilo Capital Management deployed $59.9M of net new capital in Q1 2020, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was AnaptysBio: 1,439,079 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 50% a quarter earlier.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.97M trimmed.
- Aquilo Capital Management's largest Q1 2020 buy was AnaptysBio: 1,439,079 shares worth $20.3M.
- Aquilo Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q1 2020, an estimated $12.1M increase.
- Aquilo Capital Management's biggest Q1 2020 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $5.97M.
- Aquilo Capital Management fully exited Fate Therapeutics in Q1 2020, selling an estimated $1.41M.
- Aquilo Capital Management's ten largest holdings make up 89% of its $257M portfolio in Q1 2020.
- Aquilo Capital Management opened 3 new positions and closed 1 in Q1 2020.
- Aquilo Capital Management's portfolio value fell 3.6% quarter-over-quarter to $257M.
Based on Aquilo Capital Management's 13F filing for Q1 2020, filed 15 May 2020.